Free Newsletter
Sanofi blueprints big vaccine plant for Mexico
Sanofi-Aventis CEO Chris Viehbacher journeyed to Mexico to announce a new $126 million facility to produce seasonal influenza vaccine-with a built-in option to switch to pandemic vaccines--for the Latin American market. The president of Mexico, Felipe Claderon, joined French President Nicolas Sarkozy for the announcement.
"This investment illustrates Sanofi-Aventis' local approach to global health," said Viehbacher. "This facility will benefit public health in Mexico and the Latin American region, in the context of influenza pandemic preparedness."
Once complete, Sanofi will work with Birmex--Laboratorio de Biológicos y Reactivos de México--on the manufacturing and distribution of vaccines. To be completed in four years, the plant will have the capacity to produce up to 25 million doses of new flu vaccine each year. And it will be built so that it can switch to manufacturing a pandemic vaccine in the event of an outbreak.
- read the report for more information
ALSO: Vaccine maker Sanofi Pasteur has abandoned its plans to set up operations in Pennsylvania's Lehigh Valley, which is northwest of Philadelphia. The French company had been looking to the area to relieve overcrowding at its Swiftwater, PA vaccine plant. Report
Related Articles:
Sanofi won't expand in PA's Lehigh Valley
Sanofi Pasteur plans C$100M R&D facility in Canada
Comments
What is the relationship between this Sanofi plant and the current breakout of swine flu in Mexico?
Hmm..good question
what do you think it is?
What's the relationship between MMR and Autism?
It depends on what side you are on
Post new comment
Paid Research Reports
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges
- Pharmaceuticals: United States Industry Guide
- Generic Benchmarking: Brand Erosion at Patent Expiry
- Key Players in Pharmaceutical Contract Manufacturing: Market developments, outsourcing hotspots and growth strategies




Click here to get the FierceVaccines email newsletter for FREE!
Comments (2) | Post a comment